AbbVie extends expiration of exchange present to obtain common stock of Pharmacyclics AbbVie Inc. today announced that it has prolonged the expiration of its exchange present to acquire all the exceptional shares of common stock of Pharmacyclics, Inc. To 5 p.m., New York City time, on, may 22, 2015. The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on, may 15, 2015, a complete of approximately 42,822,941 shares of Pharmacyclics common stock were tendered rather than properly withdrawn in the exchange offer validly. All other conditions and terms of the exchange offer remain unchanged.Another contribution was to revolutionize just how that biomedical products are developed. Before Langer’s group became involved with this type of study, clinicians would typically take off-the-shelf materials that somewhat looked or functioned like the tissue or organ these were studying and modify them. Langer required a different approach and utilized chemistry and chemical engineering concepts to design the biomaterials they needed. A third important contribution was helping start the field of regenerative medication and cells engineering to address the problem of donor-organ shortages. A lot more than 100,000 people in the United States are awaiting organ transplants presently, and many die while on the waiting list. Langer and colleagues produced degradable polymer scaffolds which human being cells could grow.